Prostate Cancer

EntreMed's Panzem shows activity in advanced prostate cancer

Published in Cancer Weekly, June 18th, 2002

EntreMed, Inc. (ENMD), a biopharmaceutical leader in angiogenesis research and product development, presented clinical evidence that its drug candidate Panzem demonstrated anticancer activity with disease stabilization and declining prostate-specific antigen (PSA) levels in some hormone refractory prostate cancer patients that participated in a phase II trial.

Clinical investigators also reported that Panzem, taken orally as a capsule, was safe and well tolerated and demonstrated signs of inhibiting blood vessel growth associated with the disease. The data were presented at the American Society of Clinical Oncology Annual Meeting in Orlando, Florida.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-06-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry